Corrigendum: Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset